5432132025-01-012025-03-315432132025-03-315432132024-03-315432132024-04-012025-03-315432132025-01-012025-03-31in-capmkt:OtherExpenses1Member5432132024-04-012025-03-31in-capmkt:OtherExpenses1Member5432132025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432132024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432132025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543213ROSSARINOTLISTEDINE02A801020ROSSARI BIOTECH LIMITEDMain BoardEquity2024-04-012025-03-312025-04-252025-04-17INRMillionsQuarterlyFourth quarterSingle segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries2025-04-2516:30:002025-04-2519:00:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated57956200001791000058135300003697710000338840000-200700003548900005502000018219000072934000053379200004756100000475610000144190000-1157000013262000003429900000001450000344440000-112300003332100003444400000333210000011073000026.226.21006.226.21Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 25th April, 2025.2.The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 3.The consolidated financial results include the financial results of three foreign subsidiaries - Rossari Global DMCC (incorporated on 31st May, 2024), Rossari Bangladesh Limited, Rossari International Company Limited (incorporated on 24th December, 2024), two step-down foreign subsidiaries - Rossari Biotech Trading FZE (incorporated on 7th October, 2024) and Unistar Thai Co. Ltd.(w.e.f. 10th December, 2024, 100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. - (a joint venture company of Unitop Chemicals Private Limited).4.The financial result of one non-material overseas subsidiary has been consolidated on the basis of unaudited financial statements prepared by the management.5.The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.6.The figures for the quarter ended 31st March, 2025 and 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.7.During the quarter ended 31st March, 2025, the Parent Company has allotted 7,500 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.8.The Board of Directors have recommended final dividend of Re.0.50 (25 percent of the face value of the equity share of Rs. 2 each) for the financial year ended 31st March, 2025.9.Previous year / period figures have been regrouped to make them comparable with the current year / period figures, which are not material. <BR> For ROSSARI BIOTECH LIMITED <BR> EDWARD MENEZES <BR> Executive Chairman <BR> DIN:00149205 <BR> Place : Mumbai <BR> Date : 25th April, 20252024-04-012025-03-31AuditedConsolidated208029400004009000020843030000129964400001647680000-3111500001323300000178110000670730000249585000019000960000184207000001842070000590710000-1026400004880700000135400000000097800001363780000-10250000135353000013637800000135353000001107300002024.6624.630024.6624.63Other Expenses729340000Other Expenses2495850000353534000014018700001187110000126100000026276000021100000743500007646000010513000070080000085304700003550800000573130000474504000044202000012961000012430000323100005934540000933930000104192700001210000018961840000110730000117437600001185449000011854490000100032000022307000012233900005257000046567000017416300008794100002352400002628110000286335000012258900004968650000201430000731700001224700005365720000710735000018961840000178110000-727540000-85392000000000085118000000067073000002713000000025500000857000068000000-182900000234000001244000001966470000000592040000013744300000315000001783100000000210000158512000000000000000000000072900000-77870000-183695000000050670000000012072500003857900003030000027650000165170000006490100001864900003830000190320000251700000442020000Remeasurements of the defined benefit plans-13980000-13980000Remeasurements of the defined benefit plans-12670000-12670000-3510000-3180000760000760000-11230000-10250000AuditedtrueWalker Chandiok & Co LLPtrue2025-05-31